AstraZeneca (AZN) News Today £116.06 -90.00 (-0.77%) (As of 10/25/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic DisorderOctober 25 at 7:39 AM | benzinga.comBrokerages Set AstraZeneca PLC (LON:AZN) PT at £101.62October 25 at 2:23 AM | americanbankingnews.comAstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of AstraZeneca PLC (LON:AZN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and siOctober 22 at 3:00 AM | marketbeat.comWith 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backingOctober 20, 2024 | finance.yahoo.comHere are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZenecaOctober 14, 2024 | msn.comAstraZeneca PLC ADR remains steady Tuesday, underperforms marketOctober 9, 2024 | marketwatch.comAstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority ReviewOctober 3, 2024 | finance.yahoo.comIs AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?September 30, 2024 | finance.yahoo.comAstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by AnalystsAstraZeneca PLC (LON:AZN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendSeptember 27, 2024 | marketbeat.comTop Stock Reports for Toyota, AstraZeneca & ChubbSeptember 27, 2024 | finance.yahoo.comAstraZeneca’s Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial ResultsSeptember 23, 2024 | markets.businessinsider.comLatest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer PatientsSeptember 23, 2024 | finance.yahoo.comCould The Market Be Wrong About AstraZeneca PLC (LON:AZN) Given Its Attractive Financial Prospects?September 19, 2024 | finance.yahoo.comAstraZeneca: Strong Oncology Pipeline Fuels Growth and Outperformance – Buy Rating EndorsedSeptember 18, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for AstraZeneca (AZN)September 17, 2024 | markets.businessinsider.comInsider Buying: AstraZeneca PLC (LON:AZN) Insider Buys £2,360 in StockSeptember 17, 2024 | insidertrades.comJPMorgan Chase & Co. Reaffirms Overweight Rating for AstraZeneca (LON:AZN)JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a report on Monday.September 16, 2024 | marketbeat.comMichel Demare Buys 2,000 Shares of AstraZeneca PLC (LON:AZN) StockAstraZeneca PLC (LON:AZN - Get Free Report) insider Michel Demare purchased 2,000 shares of the company's stock in a transaction dated Friday, September 13th. The stock was purchased at an average price of GBX 118 ($1.54) per share, for a total transaction of £2,360 ($3,086.18).September 16, 2024 | marketbeat.comAstraZeneca (LON:AZN) Shares Pass Above Two Hundred Day Moving Average of $11,865.94AstraZeneca (LON:AZN) Share Price Crosses Above 200 Day Moving Average of $11,865.94September 11, 2024 | marketbeat.comAstraZeneca (LON:AZN) Stock Rating Reaffirmed by Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft restated a "hold" rating and set a £110 ($144.64) price target on shares of AstraZeneca in a research report on Tuesday.September 3, 2024 | marketbeat.comSeveral Reasons for the Outperformance of Astrazeneca Plc (AZN)September 3, 2024 | finance.yahoo.comAstraZeneca (LON:AZN) Reaches New 12-Month High at $13,372.00AstraZeneca (LON:AZN) Sets New 52-Week High at $13,372.00September 2, 2024 | marketbeat.comAstraZeneca (LON:AZN) Hits New 52-Week High at $13,238.00AstraZeneca (LON:AZN) Reaches New 12-Month High at $13,238.00August 27, 2024 | marketbeat.comAstraZeneca Threatens To Move Vaccine Production Amid Reduced State SupportAugust 23, 2024 | msn.comAstraZeneca Says FDA Granted Priority Review For Imfinzi In Limited-stage Small Cell Lung CancerAugust 15, 2024 | markets.businessinsider.comAZN Aug 2024 69.000 call (AZN240816C00069000)August 12, 2024 | finance.yahoo.comAstraZeneca (LON:AZN) Reaches New 1-Year High at $12,790.00AstraZeneca (LON:AZN) Reaches New 1-Year High at $12,790.00August 12, 2024 | marketbeat.comAstraZeneca PLC (LON:AZN) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of AstraZeneca PLC (LON:AZN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued aAugust 8, 2024 | marketbeat.comTop Analyst Reports for AstraZeneca, TotalEnergies & ConocoPhillipsAugust 7, 2024 | msn.comAstraZeneca (LON:AZN) Reaches New 12-Month High at $12,792.00AstraZeneca (LON:AZN) Reaches New 52-Week High at $12,792.00August 2, 2024 | marketbeat.comAstraZeneca rises Friday, outperforms marketAugust 2, 2024 | marketwatch.comAstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average of $11,334.15AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average of $11,334.15August 2, 2024 | marketbeat.comAstraZeneca Reports ODAC's Review Of Imfinzi - Quick FactsJuly 26, 2024 | markets.businessinsider.comAstraZeneca Raises Guidance Amid High Demand for Cancer DrugsJuly 25, 2024 | bloomberg.comAstraZeneca Q2 Profit Rises, Lifts FY24 OutlookJuly 25, 2024 | markets.businessinsider.comAstraZeneca raises profit outlook on strong medicines demandJuly 25, 2024 | msn.comAstraZeneca slips despite 2024 guidance raise on medicines demandJuly 25, 2024 | msn.comAstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease MedicinesJuly 25, 2024 | finance.yahoo.comAstraZeneca PLC (LON:AZN) Plans GBX 77.60 DividendAstraZeneca PLC (LON:AZN) announced a dividend on Thursday, July 25th. Stockholders of record on Thursday, August 8th will be given a dividend of GBX 77.60 ($1.00) per share by the biopharmaceutical company on Monday, September 9th. This represents a dividend yield of 0.64%. The ex-dividend date is Thursday, August 8th. The official announcement can be accessed at this link.July 25, 2024 | marketbeat.comShore Capital Reiterates Buy Rating for AstraZeneca (LON:AZN)Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a research report on Thursday.July 25, 2024 | marketbeat.comMerck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In InfantsJuly 23, 2024 | finance.yahoo.comAstraZeneca: Strong Growth and Resilience Justify Buy RatingJuly 23, 2024 | markets.businessinsider.comAstraZeneca (LON:AZN) Stock Rating Reaffirmed by Shore CapitalShore Capital reiterated a "buy" rating on shares of AstraZeneca in a report on Friday.July 12, 2024 | marketbeat.comAstraZeneca (LON:AZN) Shares Cross Above 200-Day Moving Average of $11,163.66AstraZeneca (LON:AZN) Share Price Crosses Above 200 Day Moving Average of $11,163.66July 10, 2024 | marketbeat.comAstraZeneca (LON:AZN) Price Target Raised to GBX 74 at Jefferies Financial GroupJefferies Financial Group upped their price objective on AstraZeneca from GBX 71 ($0.90) to GBX 74 ($0.94) and gave the stock a "hold" rating in a report on Tuesday.July 2, 2024 | marketbeat.comAstraZeneca PLC (LON:AZN) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of AstraZeneca PLC (LON:AZN - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hJune 19, 2024 | marketbeat.comAstraZeneca (LON:AZN) Given "Hold" Rating at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a £110 ($139.77) price target on shares of AstraZeneca in a report on Tuesday.June 18, 2024 | marketbeat.comAstraZeneca (LON:AZN) Share Price Crosses Above 200 Day Moving Average of $10,937.73AstraZeneca (LON:AZN) Stock Price Passes Above Two Hundred Day Moving Average of $10,937.73June 18, 2024 | marketbeat.comAstraZeneca (LON:AZN) Hits New 12-Month High at $12,586.00AstraZeneca (LON:AZN) Sets New 12-Month High at $12,586.00June 5, 2024 | marketbeat.comAstraZeneca (LON:AZN) Stock Rating Reaffirmed by CitigroupCitigroup reissued a "buy" rating on shares of AstraZeneca in a research note on Tuesday.May 28, 2024 | marketbeat.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Your financial planner would NEVER tell you this (Ad)Your Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has a unique "Retirement Blueprint" that's helped people retire wealthy. This method is unlike anything your financial planner would ever suggest. Discover the blueprint here. AZN Media Mentions By Week AZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼0.590.73▲Average Medical News Sentiment AZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼42▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News HUTCHMED News Grainger News Ithaca Energy News Indivior News Bloomsbury Publishing News Global Ports News India Capital Growth News Pharos Energy News Kodal Minerals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 10/25/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredYour financial planner would NEVER tell you thisYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive g...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZN Stock Alerts